GLP-1(7-36) Acetate

CAS No. 1119517-19-9

GLP-1(7-36) Acetate( Human GLP-1-(7-36)-amide Acetate )

Catalog No. M29840 CAS No. 1119517-19-9

GLP-1(7-36) Acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 563 In Stock
10MG 896 In Stock
25MG 1311 In Stock
50MG 1748 In Stock
100MG 2353 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    GLP-1(7-36) Acetate
  • Note
    Research use only, not for human use.
  • Brief Description
    GLP-1(7-36) Acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.
  • Description
    GLP-1(7-36) Acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.(In Vitro):Cells treated with phorbol 12-myristate 13-acetate for 2 h has significantly higher active GLP-1(7-36) concentrations in the media than those in the control. The glucose treatment also increases active GLP-1 secretion from cells in dose-dependent manner. Palmitic, oleic, linoleic or linolenic acid dose-dependently stimulated active GLP-1 secretion from cells. Active GLP-1 secretion is significantly greater with unsaturated fatty acids such as oleic, linoleic and linolenic acids than with palmitic acid. The treatment of NCI-H716 cells with CPE dose-dependently increases active GLP-1 concentrations in the media. A 37% increase is observed in active GLP-1 secretion from these cells at a concentration of 0.1 % CPE.(In Vivo):Gastric administration of glucose increases active GLP-1(7-36) amide levels in the portal blood after 10 min, followed by a marked decrease at 30 min. The gastric administration of TO also increases active GLP-1 levels after 10 min, and followed by a decrease to basal levels at 60 min. Individually, glucose and TO increase the secretion of GLP-1 in a dose-dependent manner. Furthermore, the co-administration of glucose and TO additively increase peak GLP-1 levels. CPE-administered mice have higher active GLP-1 levels in the portal blood at 10 and 30 min than those in the control mice. When glucose is administered with CPE, active GLP-1 and insulin levels in the portal blood are slightly higher in CPE-administered mice than in the control mice. High-fat diet-fed C57BL/6J mice develop hyperglycaemia and impair glucose tolerance.
  • In Vitro
    Cells treated with phorbol 12-myristate 13-acetate for 2 h has significantly higher active GLP-1(7-36), amide acetate concentrations in the media than those in the control. The glucose treatment also increases active GLP-1 secretion from cells in dose-dependent manner. Palmitic, oleic, linoleic or linolenic acid dose-dependently stimulated active GLP-1 secretion from cells. Active GLP-1 secretion is significantly greater with unsaturated fatty acids such as oleic, linoleic and linolenic acids than with palmitic acid. The treatment of NCI-H716 cells with CPE dose-dependently increases active GLP-1 concentrations in the media. A 37% increase is observed in active GLP-1 secretion from these cells at a concentration of 0.1 % CPE.
  • In Vivo
    Gastric administration of glucose increases active GLP-1(7-36) amide levels in the portal blood after 10 min, followed by a marked decrease at 30 min. The gastric administration of TO also increases active GLP-1 levels after 10 min, and followed by a decrease to basal levels at 60 min. Individually, glucose and TO increase the secretion of GLP-1 in a dose-dependent manner. Furthermore, the co-administration of glucose and TO additively increase peak GLP-1 levels. CPE-administered mice have higher active GLP-1 levels in the portal blood at 10 and 30 min than those in the control mice. When glucose is administered with CPE, active GLP-1 and insulin levels in the portal blood are slightly higher in CPE-administered mice than in the control mice. High-fat diet-fed C57BL/6J mice develop hyperglycaemia and impair glucose tolerance.
  • Synonyms
    Human GLP-1-(7-36)-amide Acetate
  • Pathway
    GPCR/G Protein
  • Target
    Glucagon Receptor
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1119517-19-9
  • Formula Weight
    3394.67
  • Molecular Formula
    C149H226N40O45.xC2H4O2
  • Purity
    >98% (HPLC)
  • Solubility
    H2O : 50 mg/mL (14.73 mM; Need ultrasonic)
  • SMILES
    ——
  • Chemical Name
    Sequence:His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH2

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

Fujii Y et al. Ingestion of coffee polyphenols increases postprandial release of the active glucagon-like peptide-1(GLP-1(7-36)) amide in C57BL/6J mice. J Nutr Sci. 2015 Mar 3
molnova catalog
related products
  • PF-06882961

    PF-06882961 is an orally bioavailable glucagon-like peptide-1 receptor (GLP-1R) agonist. PF-06882961 shows mild to moderate damage to the heart, moderate to severe effects on the thymus gland (which helps with managing infection), mild to moderate stomach ulcers at the highest dose level given in the rat.

  • Survodutide

    Survodutide (BI 456906) is a dual agonist of glucagon and glucagon-like peptide 1 (GLP-1) receptors (GLP Receptor) that reduces body weight in HbA1c16 diabetes.

  • HAEGT

    HAEGT is the first N-terminal 1-5 residues of GLP-1 peptide.